Gilead Sciences Inc. has agreed to pay about $11 billion for Kite Pharma Inc. and its promising new technology for harnessing the body’s immune system to fight cancer. Gilead will pay $180 a share, representing a 29% premium over Kite’s closing price Friday. The all-cash deal would give Gilead a foothold in a new type of personalized treatment that doctors say could save patients with the most dire cases of cancer and analysts...

Source: Wall Street Journal August 28, 2017 10:30 UTC